Compare Revvity Inc (RVTY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs TORM plc — how do they compare? Revvity Inc trades at $115.88 (market cap $12.91B), while TORM plc trades at $28.86 (market cap $2.93B). The key difference: Revvity Inc is far larger — about 4.4× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.
| RVTY | TRMD | |
|---|---|---|
Market Cap | $12.91B | $2.93B |
Sector | Technology | Technology |
52-Week High | $117.75 | $34.87 |
52-Week Low | $82.26 | $18.77 |
Enterprise Value | $15.23B | $3.82B |
Dividend Yield | 0.24% | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
TRMD trades at $29.04, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI at 24.63. The company reported strong profitability with a 24.41% net margin and ROE of 15.62%, though Q1 2026 EPS missed expectations. Recent news highlights a major shareholder update from Oaktree Capital and a $0.70 dividend payment scheduled for June 2026.
Outlook remains positive with 100% analyst buy ratings, underpinned by robust cash flow and strategic positioning in tanker markets. Risks include earnings volatility and geopolitical impacts on freight rates, but valuation metrics like P/E of 8.4 suggest potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
